More than six million Americans age 65 and up are living with Alzheimer’s including more than 35,000 Nebraska residents.

As new session begins, Lt. Gov. Patrick calling for lawmakers to pass the Dementia Prevention Research Institute and offer ...

Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly treatment at home in 15 seconds. Get Real-Time ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

The Alzheimer's Accountability and Investment Act (Public Law 118-93), enacted on October 1, 2024, mandates that the National ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Cases of dementia in the U.S. are expected to steadily rise in the coming years, hitting 1 million annual cases by 2060.

Discover how a groundbreaking cognitive assessment tool is transforming early dementia detection with 99.9% accuracy and what this means for future treatment.

Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

The Lantern at Morning Pointe Alzheimer’s Center of Excellence, Collegedale, has officially completed its remodel.